🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 70 Guangzhou 63 Fuzhou 39 Chongqing 39 Hefei 36
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca62 First Affiliated Hospital of Fujian Medical University45 Merck Sharp & Dohme LLC39 Fujian Medical University Union Hospital39 Fujian Cancer Hospital35 Clear sponsor filter
Site location
Beijing70 Guangzhou63 Fuzhou39 Chongqing39 Hefei36
All 69 locations
Target enrolment
to

Trials with a site in Fuzhou

39 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
NCT07431827Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Calderasib
Merck Sharp & Dohme LLC
Phase 3
400
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Hshijiazhuang, Wuhan, Changsha
2026-03-18
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
DrugsGocatamig·Ifinatamab Deruxtecan·Atezolizumab·Etoposide
Merck Sharp & Dohme LLC
Phase 1/2
170
Beijing, Fuzhou, Guangzhou, Jiangmen, Nanchang, Shanghai, Chengdu, Hangzhou
2026-01-29
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Calderasib·Pemetrexed·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Oxaliplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
477
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen
2025-07-16
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
DrugsR-DXd·Ifinatamab Deruxtecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
144
Beijing, Chongqing, Fuzhou, Nanning, Zhengzhou, Nanjing, Shanghai
2025-05-28
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Cisplatin·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Prednisolone·Methylprednisolone
Merck Sharp & Dohme LLC
Phase 3
1,046
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Guiyang
2025-01-27
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT06596694Gastrointestinal Cancer
DrugPatritumab deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
180
Hefei, Fuzhou, Xiamen, Guangzhou, Nanning, Zhengzhou, Shanghai, Taiyuan
2024-11-03
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsLevoleucovorin·Sac-TMT·Patritumab deruxtecan·Leucovorin
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-09-20
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-08-07
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
DrugsLevoleucovorin·Leucovorin·Sacituzumab tirumotecan·Cisplatin
Merck Sharp & Dohme LLC
Phase 1/2
220
Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu
2024-06-20
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Dexamethasone
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSac-TMT·Nab-paclitaxel·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
DrugsCalderasib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
450
Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang
2024-05-03
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Gemcitabine·Pemetrexed·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Hydrocortisone·Opevesostat·Abiraterone acetate
Merck Sharp & Dohme LLC
Phase 3
1,310
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-12-31
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Hydrocortisone·Opevesostat·Prednisone Acetate
Merck Sharp & Dohme LLC
Phase 3
1,314
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing
2023-12-18
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin
2023-12-15
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsSacituzumab tirumotecan·Doxorubicin·Nab-paclitaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Pemetrexed·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,020
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2023-10-25
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015Metastatic Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
377
Hefei, Beijing, Wanzhou, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Wuhan
2023-02-14
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
DrugsSacituzumab Govitecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-02-06
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05239741Colorectal Neoplasms
DrugsLeucovorin·Irinotecan·Oxaliplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
DrugsAtezolizumab·Etoposide·Cisplatin·Carboplatin
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
DrugsBelzutifan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
DrugsTaxotere·Paraplatin·Taxol·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
DrugsCalderasib·Leucovorin·Oxaliplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
DrugsPembrolizumab·Paclitaxel·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
643
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou
2021-12-13
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706Carcinoma, Renal Cell
DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,854
Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou
2021-04-14
Active, closed
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204Small Cell Lung Cancer
DrugsOlaparib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
672
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-12-08
Active, closed
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsOlaparib·Etoposide·Durvalumab·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
870
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-07-06
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Drugs) Berahyaluronidase alfa·Olaparib·Lenvatinib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
3,500
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guanghzou, Guangzhou, Guiyang
2018-08-21
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies with a site in Fuzhou that also match the filters currently applied.

How many clinical trials are recruiting in Fuzhou?

22 of the 39 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fuzhou), 39 studies
PhaseStudiesRecruitingShare
Phase 3311479.5%
Phase 1/26615.4%
Phase 1112.6%
Phase 2112.6%

Most active sponsors

Lead sponsors with the most studies (Fuzhou)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC3922
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.